RVNL Surges on Order, Biocon Gains Health Canada Nod; Indian Stocks Rise

Indian equity benchmarks demonstrated a firm stance on Wednesday, with the Sensex and Nifty both registering approximately 1% gains in early trading. This uptrend was significantly bolstered by robust corporate developments and broad-based sectoral buying.

Key Market Movers

• Rail Vikas Nigam shares: up by 2.31% at Rs 226.35
• RVNL EPC project value: Rs 358.97 crore
• RVNL execution timeframe: 1095 days
• Biocon approval: Yesintek (ustekinumab) Autoinjector Pen by Health Canada

Rail Vikas Nigam experienced a notable surge in its share price following the announcement of a Letter of Allotment (LoA) for an Engineering, Procurement, and Construction (EPC) project. The order, valued at Rs 358.97 crore, is slated for execution within 1095 days.

In parallel corporate developments, Biocon confirmed it has secured Health Canada approval for its Yesintek (ustekinumab) Autoinjector Pen. This regulatory milestone marks a significant achievement for the pharmaceutical firm.

Economic Indicators and Investor Sentiment

The broader market rally was underpinned by strong domestic momentum, evident through healthy buying interest observed in the IT, TECK, and FMCG sectors. Further supporting the positive market sentiment, India’s Index of Industrial Production (IIP) data provided a significant boost.

• IIP expansion: 7.3% year-on-year in June 2026
• Previous month IIP (May): 5%
• IIP growth drivers: strong rebound in manufacturing activity, robust growth in electricity and gas supply segment
• Foreign institutional investors (FIIs): turned net buyers

This confluence of positive corporate news, robust industrial production figures, and renewed foreign institutional investor confidence collectively contributed to Wednesday’s constructive trading session. The market demonstrated resilience driven by specific sectoral strength and encouraging economic data.